Synbio Tech. Announced the Establishment of Cooperative Relations with ALSTEM

Synbio Technologies Announced the Establishment of Cooperative Relations with ALSTEM
Synbio Technologies, a leading international synthetic biology service company, recently announced a new partnership with ALSTEM, LLC, a United States biotech company, with the aim of developing various human CRISPR-Cas9 sgRNA libraries. These libraries will provide novel approaches for characterizing target and drug resistance genes of therapeutic significance. Related applications also promise to accelerate new drug development and advance the understanding of essential genes related to cancer. Applied to sgRNA primer chip synthesis technology, these libraries hold significant value of understanding the activity of pluripotent stem cell. These two companies will cooperate in product development for high throughput oligonucleotide synthesis and virus library applications, both with wide ranging potential for life science research.
About Synbio Technologies:
With its Syno® technology platform as a foundation, Synbio Technologies provides efficient services for next generation recombinant antibody libraries, the synthesis of genomic chromosomes, and advanced DNA data storage capabilities.
Synbio Technologies has established a complete synthetic biology platform from the synthesis of oligonucleotides and DNA fragments to the construction of chromosome genomes. Syno®3.0, the world’s most advanced next generation of synthetic biology technology platform, provides high throughput DNA chip synthesis with exceptionally low cost. At the same time, Synbio Technologies leveraged the Syno® synthetic technology platform, to design and develop an advanced biological technology transformation and application platform, the Synbio GPS platform. In alignment with the central dogma of biology, the platform connects genotype/design and phenotype/application with the new, creation enabling, synotype. Through these “design – creation – application” technologies, Synbio Tech. enables gene discovery, and thereby advances genetic understanding and its potential to improve the individual’s lives.

About ALSTEM, LLC:
Founded in 2012 by a team of scientists with deep experience at academic and industrial institutions, ALSTEM advances possibilities for stem cell research, virus packaging, genome editing, and cell immortalization. ALSTEM products have applications in wide-ranging life science areas including drug discovery, cell therapy, regenerative medicine, personalized medicine, toxicity testing, and metabolism. ALSTEM services extend the capacity and efficiency of research teams at large and small institutions worldwide. ALSTEM provides quick, responsive, expertise, with an unsurpassed value ratio of deliverables to cost. ALSTEM’s accessible scientists have a successful track record, and bring an agile mindset to meeting and exceeding client expectations with quick turnaround times.
ALSTEM puts customer needs at the center of its guiding principles. This allows ALSTEM to become an extension of the customers’ lab, and take a pride of ownership in their contribution toward mutual success.

About Synbio Technologies：

Synbio Technologies is a DNA technology company, focusing on the next generation DNA synthesis and its applications. We have built up the first integrated GPS (Genotype, Phenotype and Synotype) system aimed to a quick and easy translation or reverse translation between “Genotype” and “Phenotype” by using our proprietary “Synotype” platform. The company’s scientific capabilities encompass areas such as DNA engineering, DNA synthesis, genome synthesis, pathway synthesis, synthetic biology, pharmacogenomics, microbiology, translational biology and the applications of synthetic biology. Synbio Technologies’ team has a proven track record regarding translating scientific breakthroughs into cost effective biological solution.

Synbio Technologies
1 Deer Park Drive, Suite L-1
Monmouth Junction, NJ 08852
Logan Cummins
logan.cumminis@synbio-tech.com
732-230-3003

This release was published on openPR.